

BY E-MAIL

September 21, 2023

BSE Ltd. Phiroze Jeejeebhoy Towers 27 th Floor, Dalal Street Mumbai 400 023 E-mail: corp.relations@bseindia.com	The National Stock Exchange of India Ltd. Exchange Plaza, 5 th Flr, Plot # C/1 G Block, Bandra-Kurla Complex, Bandra (E), Mumbai 400 051. E-mail : takeover@nse.co.in
--	--

Dear Sir,


Re: Declaration under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Pursuant to Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, we are enclosing herewith our disclosure for acquisition of 1,35,79,571 equity shares of Rs. 2/- each representing 19.29% of the paid-up equity share capital of Unichem Laboratories Ltd. (506690 on BSE; UNICHEMLAB on NSE) through open offer.

Kindly acknowledge the receipt.

Thanking you

Yours faithfully
For and on behalf Ipca Laboratories Limited



Harish P. Kamath
Company Secretary

Encl: a/a

Cc: Unichem Laboratories Limited
Unichem Bhavan
Prabhat Estate, Off S.V.Road, Jogeshwari (West),
Mumbai – 400 102
E-mail id : pradeep.bhandari@unichemlabs.com
shares@unichemlabs.com

Ipca Laboratories Ltd.
www.ipca.com

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Unichem Laboratories Limited (506690 on BSE; UNICHEMLAB on NSE)		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the Acquirer	Ipca Laboratories Limited		
Whether the acquirer belongs to Promoter / Promoter Group	Yes. Acquirer belongs to Promoter / Promoter Group		
Name(s) of the Stock Exchange(s) where the shares of TC are listed	BSE Ltd. (BSE); and The National Stock Exchange of India Ltd. (NSE)		
Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a. Shares carrying voting rights	2,35,01,440	33.38%	33.38%
b. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
c. Voting rights (VR) otherwise than by equity shares	Nil	Nil	Nil
d. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
e. Total (a+b+c+d)	2,35,01,440	33.38%	33.38%



Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)
Details of Acquisition / Sale			
a. Shares carrying voting rights acquired	1,35,79,571	19.29%	19.29%
b. VRs acquired otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / Convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	Nil	Nil	Nil
d. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
e. Total (a+b+c+/-d)	1,35,79,571	19.29%	19.29%
After the acquisition, holding of			
a. Shares carrying voting rights	3,70,81,011	52.67%	52.67%
b. VRs otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
d. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	Nil	Nil	Nil
e. Total (a+b+c+d)	3,70,81,011	52.67%	52.67%
Mode of acquisition (eg. Open market / public issue/rights issue/preferential allotment/inter-se transfer etc.)	Acquired pursuant to open offer made under SEBI (SAST) Regulations		
Date of acquisition of shares or date of receipt of intimation of allotment of shares/VR/warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC	21 st September, 2023		


Ipca Laboratories Ltd.
www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005


Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837

Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)
Equity share capital/total voting capital of the TC before the said acquisition	7,04,05,750 equity shares of Rs. 2/- each amounting to Rs. 14,08,11,500/-	100%	100%
Equity share capital /total voting capital of the TC after the said acquisition	7,04,05,750 equity shares of Rs. 2/- each amounting to Rs. 14,08,11,500/-	100%	100%
Total diluted share/voting capital of the TC after the said acquisition (considering balance outstanding convertible warrants)	7,04,05,750 equity shares of Rs. 2/- each amounting to Rs. 14,08,11,500/-	100%	100%

Signature of the acquirer / Authorised Signatory:

For Ipca Laboratories Ltd.



Harish P. Kamath
 Company Secretary

Place: Mumbai

Date: 21st September, 2023

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837